Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 09, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML), which is taking place from June 14-17 in Lugano, Switzerland.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Details regarding the oral presentation follow.
Oral Presentation Details:
- Abstract Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies
- Presenting Author: P.A. Hamlin, Memorial Sloan Kettering Cancer Center
- Presentation Date and Time: June 15, 2017 at 4:40 p.m. CEST
- Location: Room A, Cinema Corso and Aula Magna (Lugano University)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
